Important differences between topoisomerase-I and -II targeting agents.
Banerji
Shantanu
S
Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada.
Los
Marek
M
D000111:Acetylcysteine / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology*; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000378:metabolism*; D004249:DNA Damage / Q000187:drug effects; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006657:Histones / Q000378:metabolism*; D006801:Humans; D008942:Mitoxantrone / Q000627:therapeutic use; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
D000970:Antineoplastic Agents; D000975:Antioxidants; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; C468783:H2AX protein, human; D006657:Histones; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D025521:Tumor Suppressor Proteins; D019772:Topotecan; D008942:Mitoxantrone; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases; D000111:Acetylcysteine